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1. INTRODUCTION {#cam42088-sec-0005}
===============

With the increasing lung cancer patients diagnosed, more and more lung cancer patients receive thoracic radiotherapy as a part of standard treatment regimen.[1](#cam42088-bib-0001){ref-type="ref"} However, approximately 16%‐30% of lung cancer patients experience moderate to severe radiation‐induced pneumonitis (RP) within the first 3 months of thoracic radiation therapy, even for those who were treated with intensity--modulated radiation therapy (IMRT).[2](#cam42088-bib-0002){ref-type="ref"} RP limits the escalation of radiation dose necessary to achieve curative effects while reducing the quality of life for patients.[3](#cam42088-bib-0003){ref-type="ref"}, [4](#cam42088-bib-0004){ref-type="ref"}, [5](#cam42088-bib-0005){ref-type="ref"} Therefore, establishing reliable predictors of RP is a critical step towards maximizing efficacy of treatment for lung cancer patients while minimizing adverse effects associated with thoracic radiation.

Multiple therapeutic and patient--related RP risk factors include performance status (PS), smoking status, chemotherapy, and dosimetric parameters.[6](#cam42088-bib-0006){ref-type="ref"} However, they are not sufficient to fully explain why under similar radiotherapy doses fraction some patients develop RP while the rest never do, which suggests a genetic basis for RP. RP genetic association studies had identified some RP susceptibility genes, further supporting a genetic basis in RP development. These RP susceptibility genes identified thus far were involved in the DNA repair pathways,[7](#cam42088-bib-0007){ref-type="ref"}, [8](#cam42088-bib-0008){ref-type="ref"}, [9](#cam42088-bib-0009){ref-type="ref"} oxidative stress pathways,[10](#cam42088-bib-0010){ref-type="ref"} cellular signaling pathways,[11](#cam42088-bib-0011){ref-type="ref"} and inflammatory response to ionizing radiation.[12](#cam42088-bib-0012){ref-type="ref"}, [13](#cam42088-bib-0013){ref-type="ref"}, [14](#cam42088-bib-0014){ref-type="ref"}

Surfactant protein D (SP‐D), a component of lung surfactants, which reduces surface tension at the pulmonary air--liquid interface[15](#cam42088-bib-0015){ref-type="ref"}, [16](#cam42088-bib-0016){ref-type="ref"}, [17](#cam42088-bib-0017){ref-type="ref"} and enhances defense against pathogens as the first line of innate pulmonary immunity,[18](#cam42088-bib-0018){ref-type="ref"}, [19](#cam42088-bib-0019){ref-type="ref"}, [20](#cam42088-bib-0020){ref-type="ref"}, [21](#cam42088-bib-0021){ref-type="ref"} has never been investigated with regard to the association between its genetic variants and the risk of RP. Previous study showed that serum levels of *SP‐D*in RP patients were elevated.[22](#cam42088-bib-0022){ref-type="ref"}, [23](#cam42088-bib-0023){ref-type="ref"}, [24](#cam42088-bib-0024){ref-type="ref"} More specifically, the genetic polymorphisms in *SP‐D* were associated with some lung injuries such as COPD,[25](#cam42088-bib-0025){ref-type="ref"} interstitial pneumonia,[26](#cam42088-bib-0026){ref-type="ref"} asthma,[27](#cam42088-bib-0027){ref-type="ref"} lung cancer,[26](#cam42088-bib-0026){ref-type="ref"} and infectious lung diseases.[28](#cam42088-bib-0028){ref-type="ref"}, [29](#cam42088-bib-0029){ref-type="ref"} Therefore, we suspected that single--nucleotide polymorphisms (SNPs) of *SP‐D* would also be associated with RP.

In this study, two endpoints of grade ≥2 or grade ≥3 RP were observed and the potential associations of *SP‐D* were explored in lung cancer patients treated with thoracic radiotherapy. To comprehensively investigate this association, the alleles, genotypes and haplotypes of tagSNPs in *SP‐D*were analyzed after clinical--risk RP factors were evaluated.

2. MATERIALS AND METHODS {#cam42088-sec-0006}
========================

2.1. Patients {#cam42088-sec-0007}
-------------

Lung cancer patients receiving thoracic radiotherapy were recruited at the Department of Radiation Oncology at Daping Hospital (Chongqing, China) between February 2006 and March 2011, and were continually recruited at the Cancer Center of Chengdu Military General Hospital (Chengdu, China) between April 2011 and April 2017. The inclusion criteria were (a) histological and cytological confirmation of lung cancer; (b) genomic DNA samples and clinical data availability; (c) patients who did not develop RP during the follow--up period must have received a radiation dose ≥40 Gy; (d) patient records with at least a 6‐month follow--up period. The exclusion criteria included (a) patients who had previous thoracic irradiation; (b) patients who had severe cardiopulmonary diseases; (c) patients who had blood relatives already enrolled in the study. Written informed consent was obtained from every patient before radiotherapy treatment. Key patient characteristics, including PS, smoking history, lung cancer stage, and chemotherapy, were all recorded. A 1‐ml peripheral blood sample was collected from each patient before radiotherapy, and genomic DNA was extracted from the blood samples using Wizard Genomic DNA Purification Kit (Promega, USA). The isolated DNA samples' purity and concentration were determined by spectrophotometric measurement of absorbances at 260 and 280 nm.

2.2. Treatment and follow‐up {#cam42088-sec-0008}
----------------------------

All patients received radiotherapy with 6‐MV X‐rays from a linear accelerator (Varian, USA). The dosimetric parameters were obtained from the treatment planning system. The median total radiation dose was 55.1 Gy (range: 22 to 72 Gy), with a mean of 2.2 Gy (range: 1.5 to 3 Gy) administered per radiation treatment. 96.2% of the patients (n = 381) received IMRT (intensity--modulated radiation therapy) and others received three--dimensional conformal radiotherapy with total radiation dose ranging from 40 Gy to 70 Gy. The dosimetric parameters for the risk of RP such as the percentage of lung volume receiving greater than 5, 10, 20, 30 Gy (V5, V10, V20, V30) were obtained from the dose--volume histograms (DVH).

During radiation therapy, patients were monitored weekly. They were checked every month from 1 to 3 months after radiotherapy and then every 3 months afterwards during follow‐up observations. Follow‐up evaluations included interval history, physical examination, chest CT or PET/CT, pulmonary functional tests, and routine blood tests. RP was assessed firstly at each follow‐up visit and diagnosed by clinical presentation and radiographic abnormalities, including ground--glass opacity, attenuation, or consolidation changes within the radiation field. Then, RP was graded by two radiation oncologists independently who were blinded from the genotyping results according to the Common Terminology Criteria for Adverse Events version 3.0. Patients with clinical symptoms such as shortness of breath, dry cough, low--grade fever, chest tightness and/or pain were graded \>2 RP. The RP patients with oxygen therapy in medical history were graded \>3 RP. The time to end--point development was calculated from the beginning of the radiation therapy for each patient to the final follow--up date October, 2017.

2.3. TagSNPs selection and genotyping {#cam42088-sec-0009}
-------------------------------------

Linkage disequilibrium of *SP‐D* and tagSNPs in *SP‐D* were analyzed by using HaploView 4.0 software (Supplementary Figure [S1](#cam42088-sup-0001){ref-type="supplementary-material"}). A total of eight tagSNPs (rs721917, rs2243639, rs726288, rs1923536, rs1998374, rs911887, rs2255326 and rs75074551), which captured 100% of 36 alleles with MAF \>0.1 with a mean r^2^ of 0.959, were genotyped by experts who were blinded to the clinical information using improved multiplex ligation detection reaction (iMLDR) method (Genesky Biotechnologies Inc, Shanghai, China). A 5% blind, random sample of study subjects was genotyped twice and the genotype concordance rate was 100% and the call rate was 100%.

2.4. Statistical methods {#cam42088-sec-0010}
------------------------

The Hardy‐Weinberg equilibrium (HWE) test was conducted via Pearson χ^2^ goodness‐of‐fit test. We observed two endpoints: development of grade ≥2 RP and development of grade ≥3 RP. The time to the end‐point was calculated from the start of radiotherapy for each patient. The SPSS 16.0 statistical package (SPSS, Chicago, IL) was used for the statistical analyses. The associations between clinical characteristics, tagSNP alleles, genotypes, haplotypes and onset time of grade ≥2 or ≥3 RP were evaluated by using univariate and multivariate Cox proportional hazard regression model. Because eight SNPs and many tests were performed, the Q value that represents a measure of significance in terms of the false discovery rate was used to adjust the significance level for individual SNPs.[30](#cam42088-bib-0030){ref-type="ref"} Q value was calculated by the Q value package implemented in the R software. Kaplan‐Meier curve and log--rank test were used to assess the differences of overall RP probability. For the positive tagSNPs, a dominant genetic model was considered. Estimation of haplotype frequencies was completed via PHASE v2.1.1 software (<http://stephenslab.uchicago.edu/software.html#phase>). All *P*‐values refer to two--sided tests, with *P* \< 0.05 considered as statistically significant.

3. RESULTS {#cam42088-sec-0011}
==========

3.1. Patients, treatment, and radiation dosimetric characteristics {#cam42088-sec-0012}
------------------------------------------------------------------

A total of 396 patients with a mean age of 59.15 years (range, 23 to 80 years) were analyzed in this study (Table [1](#cam42088-tbl-0001){ref-type="table"}). Most of them (88.13%, n = 349) had stage III/IV lung cancer (according to the 7th lung cancer TNM classification and staging system) and 97.47% (n = 386) were treated with a combination of chemotherapy and radiotherapy. The chemotherapies of these patients were irinotecan and platinum for SCLC. Pemetrexed and cisplatin were adopted as first--line chemotherapy for adenocarcinoma in NSCLC and paclitaxel and cisplatin were used for squamous cell carcinoma and adenosquamous carcinoma of the lung (ASC). Dosimetric parameters for each subvolume V5, V10, V20 and V30 were shown in Table [1](#cam42088-tbl-0001){ref-type="table"}. The median follow--up periods were 11.4 months (range: 6‐58).

###### 

Characteristics (n = 396) of lung cancer patients treated with thoracic radiotherapy

                                                   Descriptive statistics
  ------------------------------------------------ ------------------------
  Gender, n (%)                                     
  Male                                             309 (78.03)
  Female                                           87 (21.97)
  Age (y), mean ± SD                               59.15 ± 9.72
  Age group (y), n (%)                              
  ≤60                                              205 (51.77)
  \>60                                             191 (48.23)
  Histology, n (%)                                  
  SCLC                                             97 (24.49)
  NSCLC                                            299 (75.51)
  Adenocarcinoma                                   116 (38.80)
  Squamous cell carcinoma                          173 (57.86)
  Adenosquamous carcinoma                          10 (3.34)
  Tumor location in the lung, n (%)                 
  Upper lobe                                       176 (44.44)
  Middle lower lobes                               220 (55.56)
  Stage, n (%)                                      
  Ⅰ, Ⅱ                                             47 (11.87)
  ⅢA                                               99 (25.00)
  ⅢB                                               102 (25.76)
  Ⅳ                                                148 (37.37)
  PS, n (%)                                         
  ≤2                                               383 (96.72)
  \>2                                              13 (3.28)
  Smoking history, n (%)                            
  Never                                            155 (39.14)
  Ever                                             241 (60.86)
  Pulmonary lobectomy, n (%)                        
  No                                               332 (83.84)
  Yes                                              64 (16.16)
  Chemotherapy, n (%)                               
  No                                               10 (2.53)
  Irinotecan and platinum                          97 (24.49)
  Pemetrexed and cisplatin                         111 (28.03)
  Paclitaxel and cisplatin                         178 (44.95)
  Radiation dose fractionation (Gy)                 
  Mean ± SD                                        2.19 ± 0.58
  Median (P~25~, P~75~)                            2 (2,2.2)
  Radiation dose fractionation group (Gy), n (%)    
  ≤2 (conventional radiotherapy)                   276 (69.70)
  \>2 (hypofractionation)                          120 (30.30)
  Radiation dose (Gy)                               
  Mean ± SD                                        55.09 ± 7.12
  Median (P~25~, P~75~)                            56 (50,60)
  V5 (%)                                            
  Mean ± SD                                        51.22 ± 15.64
  Median (P~25~, P~75~)                            51.15 (39.2,60.9)
  V10 (%)                                           
  Mean ± SD                                        35.75 ± 12.31
  Median (P~25~, P~75~)                            35.82 (26.73,44.13)
  V20 (%)                                           
  Mean ± SD                                        20.54 ± 7.99
  Median (P~25~, P~75~)                            20 (14.9,26)
  V30 (%)                                           
  Mean ± SD                                        11.97 ± 5.85
  Median (P~25~, P~75~)                            12 (8,16)

NSCLC, nonsmall cell carcinoma; PS, performance status of ECOG score standard; SCLC, small cell carcinoma; V10 (%), percentage of the lung volume that received more than 10 Gy; V20 (%), percentage of the lung volume that received more than 20 Gy; V30 (%), percentage of the lung volume that received more than 30 Gy; V5 (%), percentage of the lung volume that received more than 5 Gy.

John Wiley & Sons, Ltd

3.2. Clinical and dosimetric variables associated with grade ≥2 or ≥3 RP {#cam42088-sec-0013}
------------------------------------------------------------------------

After radiotherapy, 88 (22.22%) patients experienced grade ≥2 RP and 38 (9.60%) patients developed grade ≥3 RP. The mean occurrence time of grade ≥2 RP or grade ≥3 RP were 2.8 months and 2.7 months, respectively. To determine whether any confounding factors were influencing the risk of RP, the association between RP and clinical--dosimetric characteristics was investigated first. The clinical variables associated with grade ≥2 RP were PS, smoking history, radiation dose and V5\~V30 (Table [2](#cam42088-tbl-0002){ref-type="table"}). The clinical variables associated with grade ≥3 RP were age, PS, radiation dose and V5\~V30 in univariate analysis (Table [2](#cam42088-tbl-0002){ref-type="table"}). In the stepwise multivariate Cox proportional hazard regression model, V30 was associated with grade ≥2 RP (HR, 1.063; 95% CI, 1.026‐1.101) and both age group (HR, 2.373; 95% CI, 1.197‐4.703) and V10 (HR, 1.042; 95% CI, 1.016‐1.070) were associated with grade ≥3 RP (Table [3](#cam42088-tbl-0003){ref-type="table"}).

###### 

Univariate analysis between clinical characteristics and grade ≥2 RP or grade ≥3 RP (n = 396)

                                            Grade ≥2 RP   Grade ≥3 RP                                    
  ----------------------------------------- ------------- ------------- --------- ------- -------------- -------
  Gender                                                                                                  
  Male                                      1                                     1                       
  Female                                    0.706         0.405‐1.230   0.219     0.791   0.348‐1.797    0.576
  Age group (y)                                                                                           
  ≤60                                       1                                     1                       
  \>60                                      1.277         0.840‐1.942   0.252     2.351   1.186‐4.659    0.014
  Histology                                                                                               
  SCLC                                      1                                     1                       
  Adenocarcinoma                            0.900         0.508‐1.595   0.719     0.760   0.323‐1.791    0.531
  Squamous cell carcinoma                   0.930         0.554‐1.561   0.785     0.764   0.351‐1.663    0.497
  Adenosquamous carcinoma                   1.440         0.432‐4.798   0.552     1.968   0.436‐8.880    0.379
  Tumor location in the lung                                                                              
  Upper lobe                                1                                     1                       
  Middle lower lobes                        0.936         0.615‐1.425   0.759     0.642   0.339‐1.217    0.174
  Stage                                                                                                   
  Ⅰ,Ⅱ                                       1                                     1                       
  ⅢA                                        1.581         0.716‐3.492   0.257     1.435   0.290‐7.109    0.658
  ⅢB                                        1.452         0.652‐3.231   0.361     3.590   0.821‐15.698   0.090
  Ⅳ                                         1.227         0.562‐2.676   0.607     2.475   0.566‐10.824   0.229
  PS                                                                                                      
  ≤2                                        1                                     1                       
  \>2                                       2.370         1.034‐5.431   0.041     3.584   1.271‐10.106   0.016
  Smoking history                                                                                         
  Never                                     1                                     1                       
  Ever                                      1.617         1.023‐2.556   0.040     1.422   0.717‐2.818    0.313
  Pulmonary lobectomy                                                                                     
  No                                        1                                     1                       
  Yes                                       0.805         0.438‐1.480   0.485     0.979   0.409‐2.340    0.961
  Chemotherapy                                                                                            
  No                                        1                                     1                       
  Irinotecan and platinum                   1.097         0.259‐4.654   0.900     0.516   0.114‐2.326    0.389
  Pemetrexed and cisplatin                  0.987         0.233‐4.188   0.986     0.367   0.079‐1.698    0.199
  Paclitaxel and cisplatin                  1.049         0.253‐4.341   0.947     0.410   0.094‐1.783    0.234
  Radiation dose fractionation group (Gy)                                                                 
  ≤2 (conventional radiotherapy)            1                                     1                       
  \>2 (hypofractionation)                   0.847         0.530‐1.355   0.489     0.509   0.224‐1.156    0.107
  Radiation dose (Gy)                       0.971         0.945‐0.997   0.032     0.951   0.916‐0.987    0.009
  V5 (%)                                    1.017         1.003‐1.030   0.016     1.024   1.003‐1.045    0.024
  V10 (%)                                   1.028         1.011‐1.046   0.001     1.042   1.015‐1.069    0.002
  V15 (%)                                   1.038         1.012‐1.065   0.004     1.058   1.018‐1.100    0.004
  V30 (%)                                   1.063         1.026‐1.101   \<0.001   1.063   1.008‐1.121    0.023

*P* were calculated by univariate Cox proportional hazard regression model.

95% CI, 95% confidence interval; HR, hazard ratio; PS, performance status of ECOG score standard; RP, Radiation Pneumonitis; SCLC, small cell carcinoma; V10 (%), percentage of the lung volume that received more than 10 Gy; V20 (%), percentage of the lung volume that received more than 20 Gy; V30 (%), percentage of the lung volume that received more than 30 Gy; V5 (%), percentage of the lung volume that received more than 5 Gy.

John Wiley & Sons, Ltd

###### 

Multivariate analysis between clinical characteristics and grade ≥2 RP or grade ≥3 RP (n = 396)

                  Grade ≥2 RP   Grade ≥3 RP                                   
  --------------- ------------- ------------- --------- ------- ------------- -------
  Age group (y)                                                                
  ≤60                                                   1                      
  \>60                                                  2.373   1.197‐4.703   0.013
  V10 (%)                                               1.042   1.016‐1.070   0.002
  V30 (%)         1.063         1.026‐1.101   \<0.001                          

Stepwise multivariate Cox proportional hazard regression model was used to select independent risk factors and the probabilities of entry and removal were 0.05 and 0.10.

95% CI, 95% confidence interval; HR, hazard ratio; RP, Radiation Pneumonitis; V10 (%), percentage of the lung volume that received more than 10 Gy; V30 (%), percentage of the lung volume that received more than 30 Gy.

John Wiley & Sons, Ltd

3.3. Univariate and multivariate analysis of tagSNPs association with grade ≥2 RP or grade ≥3 RP {#cam42088-sec-0014}
------------------------------------------------------------------------------------------------

The results of Pearson χ² goodnessof‐fit test showed that allele and genotype frequencies of all tagSNPs were in Hardy‐Weinbergequilibrium (P \> 0.05) in both the patient and the control populations, indicating our samples were a random mating population without selection. With respect to grade ≥2 RP, the associations were statistically significant for rs1998374, rs911887 and rs2255326 in multivariate analysis after adjusting confounding factors and with correction with Q value[30](#cam42088-bib-0030){ref-type="ref"} (Table [4](#cam42088-tbl-0004){ref-type="table"}). The C mutant allele of rs1998374 was protective against grade ≥2 RP in dominant genetic model (HR, 0.575; 95% CI, 0.378‐0.875) whereas the homozygous genotype of rs911887 increased the risk of grade ≥2 RP in the lung cancer patients (HR, 2.209; 95% CI, 1.251‐3.902). For rs2255326, the mutant allele A was associated with an increased risk of grade ≥2 RP (HR, 1.777; 95% CI, 1.283‐2.461) and these significant associations were still seen in both dominant (HR, 1.773; 95% CI, 1.166‐2.696) and recessive models (HR, 3.320; 95% CI, 1. 659‐6.644). Although these associations were detected between grade ≥3 RP and rs1998374 or rs2255326 in multivariate analysis, they could not reach significance level after corrected with Q value (Table [4](#cam42088-tbl-0004){ref-type="table"}).

###### 

Associations between tagSNP alleles, genotypes of *SP‐D*and grade ≥2 RP or grade ≥3 RP

  tagSNP allele/genotypes   All Radio‐therapy patients   Grade ≥2 RP   Grade ≥3 RP                                                                                                                                                        
  ------------------------- ---------------------------- ------------- ------------- -------------- --------- ------- ------- -------------- ------- ------- ---- -------- --------------- ------- ------- ------- -------------- ------- -------
  rs721917                                                                                                                                                                                                                                 
  G                         477                          110           1                                              1                                      46   1                                        1                               
  A                         315                          66            0.909         0.670‐1.234    0.542     0.587   0.924   0.681‐1.253    0.610   0.670   30   0.987    0.623‐1.563     0.955   0.962   0.928   0.585‐1.472    0.750   0.974
  GG                        143                          36            1                                              1                                      15   1                                        1                               
  GA                        191                          38            0.781         0.495‐1.232    0.288     0.416   0.813   0.515‐1.282    0.372   0.484   16   0.791    0.391‐1.599     0.513   0.785   0.714   0.351‐1.453    0.352   0.654
  AA                        62                           14            0.905         0.488‐1.677    0.750     0.750   0.921   0.497‐1.709    0.795   0.827   7    1.080    0.44‐2.649      0.867   0.962   0.965   0.391‐2.381    0.938   0.974
  rs2243639                                                                                                                                                                                                                                
  C                         612                          140           1                                              1                                      59   1                                        1                               
  T                         180                          36            0.874         0.606‐1.261    0.471     0.532   0.911   0.631‐1.315    0.618   0.670   17   0.984    0.574‐1.687     0.952   0.962   0.991   0.576‐1.704    0.974   0.974
  CC                        227                          54            1                                              1                                      22   1                                        1                               
  CT                        158                          32            0.848         0.548‐1.314    0.461     0.532   0.886   0.572‐1.373    0.588   0.670   15   0.983    0.51‐1.895      0.959   0.962   0.963   0.497‐1.865    0.910   0.974
  TT                        11                           2             0.775         0.189‐3.181    0.724     0.750   0.875   0.213‐3.602    0.854   0.854   1    0.953    0.128‐7.073     0.962   0.962   1.151   0.152‐8.701    0.891   0.974
  rs726288                                                                                                                                                                                                                                 
  C                         616                          144           1                                              1                                      62   1                                        1                               
  T                         176                          32            0.758         0.517‐1.111    0.156     0.267   0.757   0.516‐1.11     0.154   0.287   14   0.793    0.444‐1.416     0.432   0.750   0.926   0.516‐1.663    0.798   0.974
  CC                        237                          58            1                                              1                                      26   1                                        1                               
  CT                        142                          28            0.771         0.491‐1.211    0.259     0.397   0.791   0.503‐1.242    0.308   0.435   10   0.635    0.306‐1.316     0.222   0.412   0.728   0.349‐1.518    0.397   0.666
  TT                        17                           2             0.478         0.117‐1.956    0.304     0.416   0.443   0.108‐1.814    0.258   0.394   2    1.128    0.268‐4.752     0.870   0.962   1.809   0.408‐8.022    0.435   0.666
  rs1923536                                                                                                                                                                                                                                
  C                         753                          163           1                                              1                                      71   1                                        1                               
  T                         39                           13            1.548         0.880‐2.724    0.129     0.259   1.540   0.875‐2.709    0.134   0.269   5    1.375    0.555‐3.406     0.491   0.785   1.379   0.557‐3.416    0.487   0.667
  CC                        358                          76            1                                              1                                      34   1                                        1                               
  CT                        37                           11            1.376         0.731‐2.590    0.322     0.419   1.380   0.733‐2.597    0.318   0.435   3    0.842    0.259‐2.741     0.775   0.962   0.908   0.278‐2.962    0.873   0.974
  TT                        1                            1             8.091         1.115‐58.687   0.039     0.112   6.388   0.878‐46.459   0.067   0.161   1    20.259   2.706‐151.679   0.003   0.040   6.030   0.745‐48.816   0.092   0.240
  rs1998374                                                                                                                                                                                                                                
  T                         460                          116           1                                              1                                      54   1                                        1                               
  C                         332                          60            0.696         0.51‐0.951     0.023     0.074   0.695   0.509‐0.95     0.022   0.072   22   0.557    0.339‐0.915     0.021   0.077   0.587   0.357‐0.965    0.036   0.176
  TT                        133                          40            1                                              1                                      21   1                                        1                               
  CT                        194                          36            0.582         0.371‐0.913    0.018     0.068   0.584   0.372‐0.916    0.019   0.072   12   0.377    0.186‐0.767     0.007   0.046   0.380   0.187‐0.774    0.008   0.074
  CC                        69                           12            0.551         0.289‐1.051    0.070     0.183   0.549   0.288‐1.046    0.068   0.161   5    0.451    0.17‐1.196      0.109   0.219   0.510   0.19‐1.372     0.183   0.365
  CT+CC                     263                          48            0.574         0.377‐0.873    0.009     0.041   0.575   0.378‐0.875    0.008   0.040   17   0.396    0.209‐0.751     0.005   0.040   0.410   0.216‐0.781    0.007   0.074
  rs911887                                                                                                                                                                                                                                 
  T                         514                          98            1                                              1                                      41   1                                        1                               
  C                         278                          78            1.518         1.127‐2.044    0.006     0.039   1.457   1.082‐1.963    0.013   0.057   35   1.596    1.016‐2.505     0.042   0.118   1.513   0.963‐2.377    0.072   0.217
  TT                        168                          30            1                                              1                                      10   1                                        1                               
  CT                        178                          38            1.203         0.745‐1.941    0.450     0.532   1.183   0.733‐1.91     0.491   0.608   21   2.001    0.942‐4.249     0.071   0.162   1.848   0.868‐3.933    0.111   0.241
  CC                        50                           20            2.436         1.383‐4.29     0.002     0.018   2.209   1.251‐3.902    0.006   0.040   7    2.407    0.916‐6.324     0.075   0.162   2.220   0.844‐5.839    0.106   0.241
  CT+CC                     228                          58            1.457         0.938‐2.264    0.094     0.204   1.406   0.904‐2.187    0.130   0.269   28   2.089    1.015‐4.301     0.046   0.118   1.929   0.935‐3.98     0.075   0.217
  rs2255326                                                                                                                                                                                                                                
  G                         642                          125           1                                              1                                      52   1                                        1                               
  A                         150                          51            1.817         1.312‐2.516    \<0.001   0.013   1.777   1.283‐2.461    0.001   0.009   24   2.017    1.243‐3.271     0.004   0.040   1.914   1.18‐3.105     0.009   0.074
  GG                        262                          47            1                                              1                                      18   1                                        1                               
  GA                        118                          31            1.487         0.945‐2.34     0.086     0.204   1.540   0.978‐2.425    0.063   0.161   16   2.015    1.027‐3.951     0.042   0.118   2.029   1.031‐3.993    0.041   0.176
  AA                        16                           10            4.058         2.048‐8.041    \<0.001   0.013   3.320   1.659‐6.644    0.001   0.009   4    3.787    1.281‐11.194    0.016   0.069   2.975   0.999‐8.862    0.050   0.187
  GA+AA                     134                          41            1.758         1.156‐2.673    0.008     0.041   1.773   1.166‐2.696    0.007   0.040   20   2.222    1.176‐4.202     0.014   0.069   2.171   1.146‐4.11     0.017   0.113
  rs75074551                                                                                                                                                                                                                               
  G                         740                          169           1                                              1                                      70   1                                        1                               
  A                         52                           7             0.570         0.268‐1.214    0.145     0.267   0.615   0.289‐1.311    0.208   0.360   6    1.225    0.532‐2.82      0.633   0.866   1.364   0.592‐3.147    0.466   0.667
  GG                        345                          81            1                                              1                                      32   1                                        1                               
  GA                        50                           7             0.578         0.267‐1.251    0.164     0.267   0.620   0.286‐1.343    0.225   0.366   6    1.303    0.545‐3.117     0.551   0.796   1.423   0.593‐3.418    0.430   0.666
  AA                        1                                                                                                                                                                                                              

95% CI, 95% confidence interval; HR, hazard ratio; tagSNP, tag single--nucleotide polymorphisms.

Univariate analysis adopted Cox proportional hazard regression model with adjustment for no factor.

Multivariate analysis adopted Cox regression model with adjustment for V30 (%).

Multivariate analysis adopted Cox regression model with adjustment for age group and V10 (%).

*Q* was the result of multiple comparison adjustment by Q test.

John Wiley & Sons, Ltd

3.4. SNPs and cumulative probability of grade ≥2 or ≥ 3 RP {#cam42088-sec-0015}
----------------------------------------------------------

The overall probabilities of grade ≥2 or grade ≥3 RP were assessed with the Kaplan‐Meier curve and log--rank test (Figure[1](#cam42088-fig-0001){ref-type="fig"}). Patients bearing mutant allele C of rs1998374 showed lower risk for grade ≥2 RP and grade ≥3 RP compared to wild--type allele T. This protect effect was also seen in dominant model (Figure [1](#cam42088-fig-0001){ref-type="fig"}A,D). Patients with mutant allele of rs911887 (Figure [1](#cam42088-fig-0001){ref-type="fig"}B,E) or of rs2255326 (Figure [1](#cam42088-fig-0001){ref-type="fig"}C,F) had significantly higher risk for both grade ≥2 RP and grade ≥3 RP compared to wild--type allele. This risk effect was also seen in homozygous mutant genotype compared to wild--type genotype for grade ≥2 RP (Figure [1](#cam42088-fig-0001){ref-type="fig"}H,I) and in dominant model for grade ≥3 RP (Figure [1](#cam42088-fig-0001){ref-type="fig"}K,L).

![Kaplan‐Meier curve and log--rank test comparing the cumulative RP‐free probability of time to an adverse outcome between patients with alleles and genotypes of rs1998374, rs911887 and rs2255326. K‐M allele analysis of rs1998374, rs911887 and rs2255326 for grade ≥2 RP were (A‐C) and for grade ≥3 RP were (D‐F) respectively. K‐M genotype analysis of rs1998374, rs911887 and rs2255326 for grade ≥2 RP were (G‐I) and for grade ≥3 RP were (J‐L), respectively](CAM4-8-2599-g001){#cam42088-fig-0001}

3.5. Haplotype association analysis {#cam42088-sec-0016}
-----------------------------------

To further investigate the combined effect of the 3 tagSNPs (rs1998374, rs911887, and rs2255326) on the risk of RP, we estimated the frequencies of each haplotype by PHASE software and performed haplotype analysis using Cox proportional hazard regression model. There were only 4 haplotypes with over 10% frequency among eight haplotypes in the patients, other rare haplotypes were combined together as "others" in our statistical analysis (Table [5](#cam42088-tbl-0005){ref-type="table"}). The T‐A‐C haplotype was significantly associated with increased risk for both grade ≥2 RP and grade ≥3 RP when compared the most common haplotype (C‐G‐T). Lung cancer patients bearing the T‐A‐C haplotype showed approximately twofold risk of RP than those bearing the C‐G‐T haplotype for both grade ≥2 RP (HR, 1.885; 95% CI, 1.284‐2.765) and grade ≥3 RP (HR, 2.256; 95% CI, 1.248‐4.080).

###### 

Haplotype (rs1998374‐rs2255326‐rs911887) frequency estimation and haplotype association with grade ≥2 RP or grade ≥3 RP

  Haplotype   All Radio‐Therapy patients   Grade ≥2 RP   Grade ≥3 RP                                                                                                                   
  ----------- ---------------------------- ------------- ------------- ------------- --------- ------- ------------- ------- ---- ------- -------------- ------- ------- ------------- -------
  C‐G‐T       327                          59            1                                     1                             22   1                              1                      
  T‐G‐T       180                          35            1.093         0.719‐1.660   0.678     1.128   0.742‐1.714   0.572   17   1.417   0.753‐2.669    0.280   1.407   0.744‐2.661   0.293
  T‐A‐C       143                          47            1.916         1.306‐2.811   \<0.001   1.885   1.284‐2.765   0.001   22   2.345   1.299‐4.235    0.005   2.256   1.248‐4.080   0.007
  T‐G‐C       130                          30            1.311         0.845‐2.034   0.227     1.267   0.816‐1.967   0.292   13   1.493   0.752‐2.964    0.252   1.357   0.682‐2.698   0.384
  other       12                           5             2.221         0.891‐5.535   0.087     1.781   0.711‐4.458   0.218   2    2.447   0.575‐10.407   0.226   1.592   0.372‐6.811   0.531

Haplotype: rs1998374‐rs2255326‐rs911887, others included haplotype C‐A‐T, C‐A‐C, T‐A‐T, C‐G‐C with below 0.03 frequency.

Univariate analysis adopted Cox proportional hazard regression model with adjustment for no factor.

Multivariate analysis adopted Cox regression model with adjustment for V30 (%).

Multivariate analysis adopted Cox regression model with adjustment for age group and V10 (%).

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42088-sec-0017}
=============

In the present study, three tagSNPs (rs1998374, rs911887, rs2255326) were significantly associated with grade ≥2 RP and haplotype (T‐A‐C) in *SP‐D* was significantly associated with both grade ≥2 RP and grade ≥3 RP in lung cancer patients treated with radiotherapy. To our knowledge, this is the first report on an association between *SP‐D* and RP. It is worth noting that the eight tagSNPs tested captured 100% of 36 alleles in *SP‐D* with mean r^2^ of 0.959, which means 36 SNPs in *SP‐D* were investigated in this study.

RP, a complication after radiotherapy, is involved clinical characteristics, therapy--related factors and follow--up tasks. Therefore, the design and measures of RP genetic association study would be more complex than common association studies of disease.[31](#cam42088-bib-0031){ref-type="ref"}, [32](#cam42088-bib-0032){ref-type="ref"} One critical issue is the confounders. In our study, nongenetic factors including clinical information and radiotherapy--related factors were comprehensively considered before investigation of novel genetic risk factors. In addition to nongenetic factors usually analyzed in other RP genetic association studies,[7](#cam42088-bib-0007){ref-type="ref"}, [9](#cam42088-bib-0009){ref-type="ref"}, [11](#cam42088-bib-0011){ref-type="ref"}, [33](#cam42088-bib-0033){ref-type="ref"}, [34](#cam42088-bib-0034){ref-type="ref"} tumor location and more precise dosimetric parameters such as V5, V10 and V20 mentioned in some clinic studies as prediction factors for RP[5](#cam42088-bib-0005){ref-type="ref"}, [35](#cam42088-bib-0035){ref-type="ref"}, [36](#cam42088-bib-0036){ref-type="ref"}, [37](#cam42088-bib-0037){ref-type="ref"} were also analyzed in this study. We found that PS, smoking status, age and dosimetric parameters were significantly associated with RP. Whether chemotherapy was performed or not was regarded as an influencing factor of RP in some studies,[38](#cam42088-bib-0038){ref-type="ref"} but in our study only 2.5% patients received radiotherapy alone and the results did not reach statistical significance (*P* ~grade\ ≥2 ~= 0.841 and *P* ~grade\ ≥3~ = 0.097). Further analysis about different chemotherapy drugs used among patients showed no association with RP risk. Another critical issue is the stringency of RP diagnosis criteria. First, to ensure case group are strictly defined, RP diagnosis and grading should be defined properly and accurately recorded. In our study, 2 radiation oncologists diagnosed and graded RP independently and were blinded to the genetic information. Second, our follow--up schedule was considered to record RP occurrence accurately. Lastly, to reduce the possibility of false non‐RP phenotypes in the control group, the follow--up period in our study was extended to a median of 11.4 months, longer than normal occurrence time of RP (\<6 months).[6](#cam42088-bib-0006){ref-type="ref"}

The allele and genotype analysis in this study consistently revealed that the genetic variants of *SP‐D*were associated with RP. The mutant alleles of rs911887 and rs2255326 were risk factors for RP while the mutant allele of rs1998374 was a protect factor for RP. Their different effect for RP roused our interest to further analyze their combined effect for RP using haplotype analysis. Lung cancer patients treated with radiotherapy bearing C‐G‐T haplotype had about twofold higher risk of RP than those bearing T‐A‐C haplotype, strongly suggesting that the genetic variants of *SP‐D* could be a genetic biomarker in predicting RP development among lung cancer patients.

In our cohort of 396 samples, there was only one patient with a homozygous mutant genotype TT of rs1923536. Although this patient developed high--grade RP, the association between rs1923536 and RP must be reinvestigated in a large sample. Therefore, this tagSNP was excluded from haplotype analysis.

Since RP susceptibility loci could be predictors before radiotherapy, screening RP susceptibility genes has attracted researchers' interest lately. However, maybe for the reason that complex RP follow--up tasks limited the sample size, to explore RP susceptibility loci usually used not genome--wide association study (GWAS) but only candidate gene approach. Until now, RP susceptibility loci were identified in DNA repair--related, inflammation--related, angiogenesis--related and stress response--related pathways with different underlying mechanisms.[32](#cam42088-bib-0032){ref-type="ref"} SP‐D, a surfactant proteins known for its contribution to the host\'s lung immunity,[39](#cam42088-bib-0039){ref-type="ref"} has been mentioned to be biomarker of severe RP after radiotherapy.[40](#cam42088-bib-0040){ref-type="ref"} This study expanded the range of RP candidate genes to a new gene encoded pulmonary surfactant protein D, suggesting another mechanism may underlying the pathogenesis of RP. To further determine the effects of *SP‐D* SNPs and its role in RP, the functional identification of SNPs linked to variable expression levels of SP‐D and more biological studies would be performed later.

Although our patients were recruited from two hospitals, studies with larger sample size or more patients from multi‐center studies are needed to validate our findings.

Despite its limitations, this study is the first to identify novel RP susceptibility gene *SP‐D*. Three tagSNPs (rs1998374, rs911887, rs2255326) were identified as significantly associated with RP risk in the lung cancer patients treated with thoracic radiotherapy. The findings of our study may be useful in the development of genetic testing for the prediction of RP.
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